Evobrutinib - CISMeF

Preferred Label : Evobrutinib;

NCIt synonyms : 1-(4-((6-Amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino)-methyl)-piperidin-1-yl)-propenone;

NCIt definition : An inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, evobrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival.;

UNII : ZA45457L1K;

InChIKey : QUIWHXQETADMGN-UHFFFAOYSA-N;

CAS number : 1415823-73-2;

NCI Metathesaurus CUI : CL539517;

Details

Origin ID

C141427;

UMLS CUI

C4683809;

Currated CISMeF NLP mapping
- evobrutinib [MeSH Supplementary Concept]
- evobrutinib [MeSH concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- evobrutinib [MeSH Supplementary Concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
has_target
- Tyrosine-Protein Kinase BTK [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients